SDZ NKT 343 is primarily investigated for its potential in immunotherapy, particularly in the treatment of cancer. It functions as a selective activator of invariant natural killer T (iNKT) cells, which play a crucial role in bridging innate and adaptive immunity. By stimulating iNKT cells, it enhances the immune system's ability to target and destroy tumor cells. This makes it a promising candidate for developing cancer vaccines or as an adjunct in cancer immunotherapy. Additionally, its mechanism of action is being explored for potential applications in treating infectious diseases and autoimmune disorders, where modulating immune responses could be beneficial. Research is ongoing to further understand its efficacy and safety in clinical settings.